Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02608918 · ClinicalTrials.gov registry record · Phase 1

Taste Properties of HIV Inhibitor

A Phase 1 study of HIV Infections, sponsored by ViiV Healthcare.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT02608918 is a Phase 1 study of HIV Infections that has completed, run by ViiV Healthcare. The registered enrollment target is 8 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02608918, a Phase 1 study of HIV Infections, has completed, sponsored by ViiV Healthcare.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to assess the taste properties of HIV inhibitor

Conditions Studied

Interventions

  • DRUG BMS-955176

Study Locations (1)

Massachusetts

  • GSK Investigational Site - Woburn

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2016-01-05
Est. Completion 2016-05-24
Phase Phase 1

Sponsor

ViiV Healthcare

182 total trials

What the Registry Record Tells You About NCT02608918

The ClinicalTrials.gov registry entry for NCT02608918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which BMS-955176 is the first listed.

NCT02608918 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02608918 about?

NCT02608918 is a clinical study titled "Taste Properties of HIV Inhibitor". The purpose of the study is to assess the taste properties of HIV inhibitor

What is the current status of trial NCT02608918?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-01-05. Estimated completion is 2016-05-24.

What conditions does trial NCT02608918 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT02608918?

The interventions under investigation include: BMS-955176 (DRUG).

Who is sponsoring clinical trial NCT02608918?

This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02608918 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.